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Introduction 
Parkinson’s disease (PD) is a common neurodegenerative disorder affecting 100 to 
150 persons per 100 000 inhabitants. The diagnosis during lifetime is based on 
clinical examination and the cardinal features are rigidity, resting tremor, 
bradykinesia and postural instability. However, there is growing evidence, that PD 
should not be appreciated solely as movement disorder. The underlying brain changes 
also result in autonomic, sensory and neuropsychiatric disturbances.  
These neuropsychiatric symptoms include sleep disturbances, apathy, attention 
deficits, cognitive dysfunction, dementia, psychotic symptoms and depression. 
Depression is the most common neuropsychiatric complication in PD and has been 
shown to be a major determinant of impaired quality of life, often independent from the 
severity of the motor symptoms. 
Depression has commonly been considered as a “normal” psychological reaction to the 
functional impairment and poor prognosis related to a chronic neurological disease. 
However, persons suffering from diseases with comparable functional impairment are 
less likely depressed, and depression is usually not associated with functional impairment, 
and may even occur before PD is diagnosed. Therefore, intrinsic mechanisms, specific to 
PD, likely contribute as well. Several aspects of depression in PD remain to be 
explored, including the clinical symptom profile, risk factors and its biochemical 
basis. The objective of this dissertation is to explore several of these aspects, based on 
the unique longitudinal PD cohort in Stavanger established in 1992. First, in the 
general part, after a brief introduction of PD, an overview is given about the 
prevalence, clinical characteristics and treatment options for depression in PD. 
 5
List of publications 
Ehrt, U., Bronnick, K., De Deyn, P.P., Emre, M., Tekin, S., Lane, R., Aarsland, D., 
2007. Subthreshold depression in patients with Parkinson's disease and 
dementia--clinical and demographic correlates. Int J Geriatr Psychiatry, 22, 
980-5. 
Ehrt, U., Bronnick, K., Leentjens, A.F., Larsen, J.P., Aarsland, D., 2006. Depressive 
symptom profile in Parkinson's disease: a comparison with depression in 
elderly patients without Parkinson's disease. Int J Geriatr Psychiatry, 21, 252-
8. 
Reijnders, J.S., Ehrt, U., Weber, W.E., Aarsland, D., Leentjens, A.F., 2008. A 
systematic review of prevalence studies of depression in Parkinson's disease. 
Mov Disord, 23, 183-9; quiz 313. 
Sharp, S.I., Ballard, C.G., Ziabreva, I., Piggott, M.A., Perry, R.H., Perry, E.K., 
Aarsland, D., Ehrt, U., Larsen, J.P., Francis, P.T., 2008. Cortical serotonin 1A 
receptor levels are associated with depression in patients with dementia with 
Lewy bodies and Parkinson's disease dementia. Dement Geriatr Cogn Disord, 
26, 330-8. 
Ehrt, U., Larsen, J.P., Aarsland, D., 2009. Pain and its relationship to depression in 
Parkinson disease. Am J Geriatr Psychiatry, 17, 269-75.  
Ehrt, U., Broich, K., Larsen, J.P., Ballard, C., Aarsland, D., 2009. Use of  
anticholinergic drugs and impact on cognition in Parkinson’s disease: A cohort 
study. submitted to Journal of Neurology, Neurosurgery and Psychiatry. 
 
 6
Contents 
SCIENTIFIC ENVIRONMENT ........................................................................................................ 2 
ACKNOWLEDGEMENTS................................................................................................................. 3 
INTRODUCTION................................................................................................................................ 4 
LIST OF PUBLICATIONS................................................................................................................. 5 
CONTENTS ......................................................................................................................................... 6 
1. PARKINSON’S DISEASE: A BRIEF INTRODUCTION .................................................... 9 
1.1 DEFINITION AND DIAGNOSIS .................................................................................................... 9 
1.2 EPIDEMIOLOGY...................................................................................................................... 10 
1.3 CLINICAL PRESENTATION AND COURSE ................................................................................. 10 
1.4 PATHOLOGY .......................................................................................................................... 11 
1.5 ETIOLOGY ............................................................................................................................. 11 
1.6 MANAGEMENT ...................................................................................................................... 11 
1.7 PSYCHIATRIC SYMPTOMS IN PARKINSON’S DISEASE .............................................................. 12 
2. DEPRESSION AS PSYCHIATRIC DISORDER ................................................................. 14 
3. EPIDEMIOLOGY, COURSE AND CONSEQUENCES OF DEPRESSION IN PD ........ 16 
4. CLINICAL CHARACTERISTICS OF DEPRESSION IN PD ........................................... 18 
4.1 THE PSYCHOPATHOLOGICAL PATTERN OF DEPRESSION IN PARKINSON’S DISEASE ................. 18 
4.2 DEPRESSION AND ITS ASSOCIATION WITH OTHER CLINICAL FEATURES IN PARKINSON’S DISEASE 19 
5. THE DIAGNOSIS OF DEPRESSION IN PD ....................................................................... 21 
5.1 CLINICAL CRITERIA ............................................................................................................... 21 
5.2 PSYCHOMETRIC MEASUREMENTS .......................................................................................... 22 
6. AETIOLOGY OF DEPRESSION IN PD .............................................................................. 25 
 7
6.1 BIOLOGICAL VERSUS PSYCHOLOGICAL EXPLANATIONS .......................................................... 25 
6.2 PAIN AND DEPRESSION IN PD ................................................................................................. 27 
6.3 BRAIN CHANGES OF DEPRESSION IN PD .................................................................................. 28 
6.3.1 Serotonin ..................................................................................................................... 28 
6.3.2 Noradrenalin ............................................................................................................... 30 
6.3.3 Dopamine .................................................................................................................... 30 
6.3.4 Acetylcholine ............................................................................................................... 32 
6.4 STRUCTURAL AND FUNCTIONAL IMAGING .............................................................................. 33 
7. MANAGEMENT OF DEPRESSION IN PD ......................................................................... 35 
7.1 PSYCHOSOCIAL AND PSYCHOTHERAPEUTIC STRATEGIES ........................................................ 36 
7.2 PHARMACOTHERAPY .............................................................................................................. 37 
7.3 BIOLOGICAL, NON-PHARMACOLOGICAL AGENTS .................................................................... 39 
7.3.1 Electroconvulsive therapy ........................................................................................... 39 
7.3.2 Transcranial magnetic stimulation ............................................................................. 40 
7.3.3 Deep brain stimulation ............................................................................................... 40 
8. THIS STUDY ............................................................................................................................ 42 
8.1 AIMS OF THIS STUDY .............................................................................................................. 42 
8.2 METHODS ............................................................................................................................... 43 
8.2.1 Design ......................................................................................................................... 43 
8.2.2 Methods for the systematic review .............................................................................. 43 
8.2.3 Patient selection .......................................................................................................... 43 
8.2.4 Diagnosis and rating of PD ........................................................................................ 44 
8.2.5 Diagnosis and rating of depression ............................................................................ 45 
8.2.6 Diagnosis of dementia and cognitive assessment ....................................................... 47 
 8
8.2.7 Techniques used to study brain tissue ........................................................................ 47 
8.3 RESULTS ................................................................................................................................ 47 
8.3.1 Study 1 ........................................................................................................................ 47 
8.3.2 Study 2 ........................................................................................................................ 48 
8.3.3 Study 3 ........................................................................................................................ 49 
8.3.4 Study 4 ........................................................................................................................ 50 
8.3.5 Study 5 ........................................................................................................................ 51 
8.3.6 Study 6 ........................................................................................................................ 51 
8.4 DISCUSSION ........................................................................................................................... 52 
8.4.1 Methodological critique ............................................................................................. 52 
8.4.2 Study design and patient selection ............................................................................. 52 
8.4.3 Diagnosis of PD and psychometric methods.............................................................. 54 
8.4.4 Findings in context ..................................................................................................... 57 
8.4.5 Implications ................................................................................................................ 60 
SOURCE OF DATA .......................................................................................................................... 62 
 
 9
1. Parkinson’s disease: A brief Introduction 
1.1 Definition and diagnosis 
Parkinson’s disease (PD) is a chronic-progressive and disabling neurological disorder 
and the second most common neurodegenerative disease after Alzheimer’s disease. 
Pathologically, PD is defined by nigrostriatal loss of dopaminergic cells and Lewy 
bodies in the surviving cells on autopsy. It is manifested clinically by a broad 
spectrum of motor and non-motor features. The four cardinal features of PD can be 
grouped under the acronym TRAP: tremor at rest, rigidity, akinesia (or bradykinesia) 
and postural instability. This syndrome is labeled “parkinsonism” and may also occur 
in other medical conditions than idiopathic PD, such as dementia with Lewy bodies, 
cerebrovascular disease, the so called parkinsonian plus syndromes or as side effect 
after administration of neuroleptic medication. The presence of akinesia and one of 
the other symptoms are considered sufficient for the clinical diagnosis of 
parkinsonism. Diagnostic criteria have been developed by the UK Parkinson’s 
Disease Society Brain Bank and the National Institute of Neurological Disorders and 
Stroke (NINDS) 1. Other diagnostic criteria for clinical subgroups of the disease 
classified at different levels of confidence were proposed by Larsen et al. 2. Flexed 
posture and motor blocks (freezing) have been included among classic features of PD 
3. Despite recent advances in imaging and genetics of PD, its diagnosis is typically 
based on the presence of a combination of cardinal motor features, associated and 
exclusionary symptoms, and response to levodopa 4. The Unified Parkinson’s Disease 
Rating scale (UPDRS) is the most established scale for assessing motor dysfunction, 
disability and impairment 5.  
 10
1.2 Epidemiology 
Incidence and prevalence of PD increase with age, but published numbers vary 
widely across studies and countries, which is probably due to differences in 
methodology and diagnostic criteria. However, metaanalyses indicate that about 1.6% 
of persons 65 years of age or older are affected by the disease 6. The best incidence 
studies give a rate of about 17 per 100 000 per year in the overall population, the 
highest incidence is generally between 70 and 79 years of age 7. In a recent incidence 
study covering near ¼ of the total Norwegian population, Alves et al. found the 
annual incidence rate to be 12.6 per 100 000 inhabitants, age-adjusted to the 
1991European population structure 8. There is good evidence that men are, in general, 
about 1.5 times more likely to develop Parkinson’s disease than women, this 
difference is not the same across different studies, and is more pronounced in (and 
possibly restricted to) people with an older age of onset and in Western populations 9. 
Healthcare costs for the management of PD are substantial. The direct health care 
costs of PD in the United States were estimated at $10,349 per patient per year and 
are expected to rise in the future due to the aging population worldwide, and 
following this, the increasing number of affected patients 10. 
1.3 Clinical presentation and course 
Disease presentation is usually unilateral and insidious. Although there are wide 
inter-individual variations, the course of disease is relentlessly progressive, with 
gradually increasing motor symptoms, and development of a range of non-motor 
symptoms, increasing functional impairment and disability, such as autonomic 
dysfunction, pain, skin problems, sleep disturbances and neuropsychiatric symptoms 
(see below) 11. Patients suffering from PD live with significant functional 
impairment, a poor health-related quality of life (HRQOL), and increased mortality 
compared with the general population 11 12. 
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1.4 Pathology 
In addition to the defining loss of nigrostriatal dopaminergic neurons, a wide range of 
other brain regions and neurotransmitter systems are involved, and according to the 
Braak hypothesis 13, there is a sequential rostral progression of the pathological 
involvement. Brain stem nuclei such as serotonergic raphe nuclei, the adrenergic 
locus coeruleus, as well as dopaminergic nuclei such as ventral tegmental area are 
involved in the majority of cases. The major cholinergic nuclei in the basal forebrain 
and limbic structures are also involved rather early in course, and in the final stages, 
neocortical involvement is common. Whereas the nigrostriatal pathology is the main 
cause of the motor symptoms, the widespread extra-striatal pathologies probably 
contribute to the wide variety of non-motor symptoms in PD 14-16, although the exact 
relationship between non-motor symptoms and brain changes are poorly understood. 
1.5 Etiology 
Etiology is largely unknown, but it is hypothesized that PD is caused by interplay of 
genetic and environmental causes. Recent insights into genetics of Parkinson’s 
disease (PD) have enhanced our understanding of basic disease mechanisms, for 
example the central role of -synuclein, the key element of the Lewy body. Mutations 
in the -synuclein gene (SNCA) were found in autosomal dominant PD. Several 
other mutations have been identified, and contribute to familial cases of PD. For 
example, mutations in the parkin gene contribute in the pathogenesis of early onset 
autosomal recessive parkinsonism 17. However, the majority of PD cases are sporadic, 
suggesting that genetic factors are multifactorial. 
1.6 Management 
The current treatment of PD is mainly medical and its aim is to alleviate the 
symptoms. A cure is not available. Treatment of Parkinson’s disease is complex 
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because of the chronic-progressive course of the disease and the wide range of motor 
and non-motor symptoms demanding different strategies. Drugs include l-dopa, 
dopamine receptor agonists, anticholinergic drugs, and antiglutamatergic drugs 18. L-
dopa remains the treatment of choice. There is an ongoing debate how early in the 
course of the disease one should initiate medication 19. The early use of dopamine 
agonists is beneficial in younger Parkinsonian patients. Nonergot dopamine agonists 
have milder side effects. Dopamine agonists, catechol-o-methyltransferase inhibitors, 
amantadine and apomorphine have differing but beneficial roles in the management 
of levodopa side effects 19. These drugs can improve motor symptoms in the majority 
of cases, although the underlying pathological process is probably not affected. 
However, with the progression of the disease, the effect is usually less pronounced, 
and adverse events and drug-related complications such as motor fluctuations with 
on-off periods, dyskinesias, psychosis and delirium occur in many patients and limit 
the usefulness of these drugs, 
Since basal ganglia circuits and their disturbances in PD became better understood, 
stereotaxic surgery has had a renaissance in PD 20. One important breakthrough in 
this field has been the introduction of high-frequency stimulation (deep brain 
stimulation, DBS), a method that has substituted the classical lesioning methods 
previously used in stereotactic and functional neurosurgery 21. The most common 
targets for DBS are subthalamic nucleus (STN), internal pallidal segment and 
ventrointermedial thalamic nucleus 20. Transplantation of dopamine-producing cells 
may become another surgical approach for treating PD when the technical and ethical 
problems related to this method are resolved. 
1.7 Psychiatric symptoms in Parkinson’s disease  
Non-motor symptoms of PD have been increasingly recognized as a major cause of 
disability. In addition to autonomous dysfunction and pain, neuropsychiatric 
disorders including cognitive impairment are particularly common 11. A wide variety 
of neuropsychiatric symptoms occur in PD, including visual hallucinations 22, anxiety 
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23, depression 24 25, apathy 26, cognitive impairment 27, and impulse control disorder 28 
29. These symptoms tend to cluster into syndromes, and typically affective, psychosis 
and apathy syndromes have been identified in PD 30. Depression is the most common 
psychiatric disorder diagnosed in patients with Parkinson’s disease 31, and is the topic 
of the current thesis. 
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2. Depression as psychiatric disorder 
 
The term depression is used to describe a mood, a symptom, a symptom constellation 
(syndrome) as well as a group of specific psychiatric disorders. Due to the absence of 
reliable biological markers, the diagnosis of the specific psychiatric disorder 
depression is still based exclusively on symptoms and signs. 
Major depressive disorder (MDD), dysthymic disorder (DD), minor depression and 
depression not otherwise classified (DDNOS) are the group of disorders in the 
Diagnostic and Statistical Manual for Mental Disorders of the American Psychiatric 
Association characterized by depressive symptomatology 32. 
The diagnosis of major depressive disorder or major depression (MD) requires the 
presence of depressive mood or loss of interest and pleasure in once-pleasurable 
activities for at least 2 weeks, accompanied by a varying combination of other 
depressive symptoms, among them loss of appetite, sleeping disturbances, 
concentration difficulties, psychomotor restlessness, feelings of worthlessness or guilt 
(the exact criteria are displayed in Table 1). Some individuals experience only one 
single episode, but often, individuals suffer from multiple major depressive episodes. 
Severe depressive illness may be accompanied by psychotic symptoms, such as a 
break with reality, hallucinations, and delusions.  
Minor depression is a mood disorder with fewer symptoms and less impairment 
compared with major depression. DSM research criteria for minor depression are in 
the DSM-IV appendix and require the presence of only two of nine symptoms (see 
table 1). Depressive episodes may occur once in a person’s lifetime, but more often, 
they are recurrent. Dysthymia or dysthymic disorder are less severe conditions with 
depressive symptomatology that may not disable a person but can hinder one from 
functioning or feeling well. They are considered as rather chronic disorders. To 
diagnose it, symptoms have to be present for two years or longer. People with 
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dysthymia may also experience one or more episodes of major depression during 
their lifetimes.  
 
Table 1) DSM-IV-TR criteria for major and minor depression 
Depressive episode Criteria 
Major depressive 
episode 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. Persistence and general pervasiveness of 5 or more of 9 
potential symptoms during the same 2-week period that represent 
a change from previous functioning; at least one of the symptoms 
is either (1) depressed mood or (2) loss of interest or pleasure that 
is present most of the day, nearly every day, as indicated by either 
subjective report or observations made by others. 
 
1) Depressed mood 
2) Markedly diminished interest or pleasure in all, or almost 
all, activities 
3) Loss or gain in weight or appetite 
4) Insomnia or hypersomnia 
5) Psychomotor agitation or retardation 
6) Fatigue or loss of energy 
7) Feelings of worthlessness or excessive or inappropriate 
guilt 
8) Diminished ability to think or concentrate, or 
indecisiveness 
9) Recurrent thoughts of death, recurrent suicidal ideation 
without a specific plan, or a suicide attempt or a specific 
plan for committing suicide 
 
B. Symptoms do not meet criteria for a DSM mixed episode 
(presence of phenomena of both a manic and a 
depressive episode). 
 
C. Symptoms cause clinically significant distress or functional 
impairment. 
 
D. Symptoms are not due to the direct physiological effects of a 
substance or a general medical condition. 
 
E. Symptoms are not better accounted for by bereavement. 
  
Minor depressive 
episode  
Requires only 2 of the 9 symptoms above, but one must be either 
depression/sadness or loss of interest/pleasure. 
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3. Epidemiology, course and consequences of 
depression in PD 
The differential diagnosis of depression in PD is broad, including states of 
demoralization, adjustment disorders, major mood disorders (major depression, 
dysthymia, or bipolar disorder), minor depression, and depressive symptoms not 
fulfilling diagnostic criteria (subsyndromal depression). In addition, apathy and 
fatigue may mimic depression. Depression has a major impact on functional ability as 
well as on the quality of life of PD patients and their caregivers 33-36. In some studies, 
depression was revealed as the strongest predictor for impaired quality of life 34 35. 
Depression is also associated with lower cognitive functioning and increased 
mortality 37 38. Despite this, in many PD cases, depression is not diagnosed 
sufficiently and thus, under-treated 39 40.  
The prevalence of depression or depressive syndromes in PD reported in the literature 
varies widely, ranging from 2.7% to 76% 24 41 42. Several reasons for this variation can 
be given, for instance the nature of the study population, how depression is defined 
and the way it is diagnosed. Also the applied statistical methods may influence the 
numbers. Studies in outpatient and inpatient samples tend to report higher prevalence 
rates, whereas rather lower prevalence numbers are reported in studies measuring 
depressive symptoms in community-based studies. Studies using diagnostic criteria 
for depression strictly, such as DSM IV or the International Classification of Diseases 
(ICD) of the World Health Organization (WHO) yield the lowest rates 41.  
Furthermore, the approach to such criteria may influence prevalence numbers. 
Important depressive symptoms like insomnia, weight loss psychomotor retardation 
or loss of energy are also frequent symptoms in PD, sometimes in the absence of 
depressed mood 43. One has to choose either an “inclusive” approach and to consider 
such ambiguous symptoms as belonging to the depressive syndrome or not to do so 
and choosing the “exclusive” approach, which yields lower prevalence rates. This 
problem is discussed more in detail in the section “Diagnosis of depression in PD”. 
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Self-report rating scales tend to give higher prevalence rates than observer-rated 
instruments. Prevalence rates are influenced by the syndromes included in the study: 
major depressive disorder only or less severe syndromes such as dysthymia and 
minor depression. When using point-prevalence, the rates are lower than in studies 
using monthly or lifetime prevalence. 
There is a lack of a systematic review of prevalence studies taking all these factors 
and the different settings and approaches to diagnosis of depression in PD into 
account, which make it difficult to estimate the extent to which depression is 
accompanying PD.  
Neither the prevalence nor the severity of depression seem to have any clear 
relationship to the course of PD. Patients both in early and late phases of the disease 
can suffer from depression. It was even shown that depression, especially major 
depression (MD) may predate the onset of the motor symptoms 44.  
Little is known about the natural history of depression in PD. The existing 
longitudinal data suggest that in some patients the course is chronic or variable with 
repeated remissions and relapses of depression and that the more severe cases seem to 
become chronic. Starkstein et al. found that 56% of patients with MD still suffered 
from MD at follow up, and 89% were still depressed when also cases with minor 
depression were included 45. In another study, cases with less severe depression were 
more likely to be significantly improved at follow up than those with severe 
depression 46. Limitations with the few longitudinal studies are that the cohorts were 
small and selected, and that follow-up time was rather short. Thus, further studies 
with more adequate design are needed. 
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4. Clinical Characteristics of depression in PD 
4.1 The psychopathological pattern of depression in 
Parkinson’s disease  
Several studies have explored the hypothesis that the symptom profile of depression 
in patients with PD differs from that in patients without PD. From a theoretical point 
of view; it has been suggested that the neurotransmitter disturbances underlying 
depression in PD may differ somewhat from those in ‘common’ depression regarding 
localisation, distribution and severity 47 and that such differences result in a specific 
phenomenological symptom pattern. This would have clinical implications, since 
modern antidepressants provide differential pharmacological strategies targeting 
specified depressive symptoms, e.g. specific monoamine transmitter disturbances. As 
early as in 1923, Friedrich H. Lewy described depressive patients with PD to be 
moody, irritable and weepy from a clinical view 48. More recent studies focusing on 
the clinical  features of depression in PD,  reported distinctive characteristics in PD-
related depression with less classical ‘endogenous’ depressive symptoms such as 
feelings of guilt, suicidal ideation, but more somatic symptoms such as anxiety, sleep 
disturbances and concentration difficulties. “Atypical depression” accompanied by 
anxiety or comorbid anxiety disorders were reported by Schiffer et al. 49. Brown 
found that depression in PD was characterized by loss of interest and poor 
concentration in one study 50 and by a low degree of feelings of guilt and self blame 
and a relative lack of delusions and hallucinations in another  51. Ehmann et al. 
compared depressive symptoms in 45 PD patients to those in 24 matched patients 
with other chronic disabling diseases not involving a loss of central monoamines and 
not differing on a measure of functional disability 52. PD subjects had significantly 
higher BDI total scores and higher scores on BDI items reflecting cognitive-affective 
and somatic depressive symptoms. According to the authors, these findings support 
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the hypothesis that depressive symptoms in PD are not solely a psychological 
reaction to disability. 
In contrast, other studies found the psychopathological features of depression in 
patients with and without PD to be similar and therefore likely to have a common 
pathogenetic basis. The difference in some aspects of symptomatology might be due 
to some additional pathogenetic factors, although this would not necessarily confirm 
the hypothesis that depression in PD is a distinct subtype of depressive disorders 53 54.  
To date, few studies have directly compared the phenomenology of depression in PD 
and MD. Such information may help in diagnosing depression in PD and enhance our 
understanding of the underlying neurochemistry of depression in PD, with potential 
therapeutical implications.  
4.2 Depression and its association with other clinical 
features in Parkinson’s disease 
Attempts have been made to understand the underlying neurobiology of depression in 
PD by examining its relationship to other clinical features. Depressed patients with 
PD are more likely female 25 and to have a history of former depression 55, and 
patients with motor symptoms on the right side and assumed left brain pathology 
were more depressed than those with left-sided symptoms 55. In a series of studies, 
depression was more frequent in those subjects with a predominant akinetic-rigid 
syndrome than in those with a predominant tremor or mixed phenotype 56 57. In a 
small study study by Menza et al., temporary dysphoria and anxiety were found to 
follow motor fluctuations 58. Most patients rated themselves worse during off-states, 
and better during on-states on a mood scale. Such brief mood disturbances commonly 
do not meet the criteria for an existing mood disorder, but are often experienced as 
distressing by the patients. This effect was stable in the majority of patients, 
regardless of concomitant dyskinesia, but some worsened again, when the on-state 
was accompanied by dyskinesia. Thus, such mood fluctuations can be an expression 
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of central dopaminergic changes and a direct effect of levodopa therapy on mood, or 
alternatively, as a psychological secondary change associated with disability due to 
motor symptoms 59. The results argue also for a complex etiology of depression in 
PD.  
Mayeux et al. reported that depressed patients with Parkinson's disease were younger 
than non-depressed patients 60. This finding has been replicated by others 61 62, even 
after controlling for the duration of PD 62. 
However, the findings are conflicting, and consensus has not yet been reached 
regarding the clinical correlates of depression in PD 63.  
Common comorbid non-motor symptoms of depression in PD are cognitive 
impairment and dementia, anxiety, psychosis, apathy, sleeping and sexual 
disturbances 25 31 64-67. Several studies have explored the relationship between 
depression and cognitive impairment, both in the general population and in PD. 
Starkstein et al. reported that depression scores in patients with PD accounted for 
most of the variance in MMSE score and had more impact on cognitive function than 
age and duration of illness. However, only patients with PD and major, but not minor 
depression scored significantly lower on MMSE than non-depressed patients 55. In 
the Stavanger community-based sample, Tandberg et al. found that a MMSE score 
<24 increased the probability of major depression by 6.6 66. It is not yet clear whether 
the cognitive deficits are a result of severe depression or vice versa in PD. A 
relationship between depression and cognitive impairment has been reported also in 
patients without PD 68. Starkstein et al. assessed PD patients prospectively and found 
that the depressed subgroup showed a significant steeper decline on cognitive 
function than the non-depressed subgroup. However, patients treated for depression 
had a milder decline of their cognitive scores than untreated patients, suggesting that 
adequate management of depression may delay cognitive impairment 45.  
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5. The diagnosis of depression in PD 
5.1 Clinical criteria 
Depression is usually diagnosed according to the criteria of the 4th edition of the 
Diagnostic and Statistical Manual of Mental Disorders 69 or the ICD-10 Classification 
of Mental and Behavioral Disorders 70. However, the diagnosis of a depressive 
disorder according to DSM IV or ICD-10 cannot be made, when depression is “due 
to a general medical condition”. No guidelines are given for how to apply this 
criterion. Especially in PD this exclusion criterion is difficult to apply in individual 
patients, since it is usually unclear whether or not a symptom is caused by the somatic 
disease. Therefore, the strict use of these criteria in PD would exclude a significant 
part of patients with clinically significant depressive symptoms 71 and cannot be 
applied without restrictions. In the revised version of DSM (DSM IV-TR) the authors 
recommend diagnosing “mood disorder due to Parkinson’s disease”. However, 
researchers in this field have stated for a long time that there is a need of clear 
diagnostic criteria for PD related depression.  
Many depressive symptoms like insomnia, weight loss, psychomotor retardation or 
loss of energy are also frequent symptoms in PD, even if the patient doesn’t report 
depressed mood 43. Therefore, symptom overlap between depression and PD is a 
well-known diagnostic problem in PD and assessments exclusively based on observer 
or self-ratings, are therefore of questionable validity 72. Moreover, many of the 
depressive symptoms have a lower specificity in PD. Concentration difficulties, 
sleeping problems, psychomotor retardation or loss of energy are symptoms typical 
for both PD and depression. Therefore, when diagnosing depression in PD, one has to 
choose an exclusive or a more inclusive approach. The latter allows including also 
the somatic ambiguous features which may be interpreted as depressive symptoms or 
as being part of the neurological disease. Sleeping difficulties or restlessness are such 
symptoms. However, the inclusive approach results in higher depression rates. It may 
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also be difficult to diagnose depression in patients with cognitive impairment, which 
is common in PD, due to reduced ability to abstract thinking, self-awareness and 
communication abilities. 
Thus, the recently recommended provisional diagnostic consensus criteria for 
depression for in PD were gratefully welcomed 71. Modifying DSM-IV criteria for 
MD, the participants of an expert workshop recommended: (1) a rather inclusive 
approach to symptom assessment to enhance reliability of ratings in PD and avoid the 
need to attribute symptoms to a particular cause; (2) the inclusion of subsyndromal 
depression in clinical research studies of depression of PD; (3) the specification of 
timing of assessments for PD patients with motor fluctuations; and (4) the use of 
informants for cognitively impaired patients.  
5.2 Psychometric measurements 
 
Cut-off values from different depression scales or DSM criteria have commonly been 
used to diagnose depression in PD. However, the most common depression scales 
assess psychopathological as well as somatic symptoms, which do not necessarily 
represent depressive symptoms in patients with PD. When choosing an “inclusive” 
instead of an “exclusive approach”, (see above), one has to consider sleeping 
problems or concentration difficulties as depressive symptoms which consequently 
leads to higher depression scores.  
The expert group mentioned above 73 concluded that there are validated and widely 
accepted depression scales to be used in patients with PD, such as Beck Depression 
Inventory (BDI), Hamilton depression rating scale (HAM-D), and MADRS. Less 
data was available on Center for Epidemiologic Studies Depression Scale (CES-D) 
and Cornell Scale for Depression in Dementia (CSDD). Observer-rated scales (e.g., 
HAM-D and Montgomery-Åsberg Depression Rating Scale [MADRS]) have better 
psychometric properties than self-rated scales. Depression scales are useful as 
screening instruments and rating scales, and to follow symptoms over time. 
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Depending on whether high sensitivity or high specificity is required, adaptations of 
cut-off scores can be necessary. For screening purposes, HAM-D, BDI, Hospital 
Anxiety and Depression Scale (HADS), MADRS, and Geriatric Depression Scale 
(GDS) are recommended. HAM-D and MADRS as well as the BDI and the Zung 
Self-Rating Depression Scale (SDS) are more useful and valid when assessment of 
severity is important. Of note, a rating scale can only supply but never substitute the 
clinical diagnosis, and thus, the diagnosis of depression should ideally not be 
exclusively made by a score on a scale. Structured clinical interviews such as SCID, 
MINI etc can be used in addition, but have not yet been validated in PD. There is not 
one generally accepted, “best” depression rating scale for PD patients. MADRS, 
GDS, and CSDD may be useful in patients with dementia. A complicating issue is the 
fact that patients often perceive their condition differently in an off period than during 
an on period. Accordingly, fluctuations should be recorded, and also any variation in 
depression related to such fluctuations. Although the HAMD has several ambiguous 
items, which can be expression of both depression and PD, such as insomnia, 
agitation or gastrointestinal symptoms, by using adjusted cut-offs, it has shown the 
best psychometric properties compared to DSM-IV criteria. The HADS and GDS 
have fewer overlapping, somatic items and therefore, may be better when comparing 
patients at different stages of PD. In line with the NINDS recommendations 71 “loss 
of pleasure” or anhedonia is more specific to depression, while “loss of interest” is 
also considered as a symptom of apathy and often occurs in patients without 
depression. More research is required on the sensitivity, specificity, and positive and 
negative predictive values of each scale for major depressive disorder in PD, in 
particular the Cornell Scale for Depression in Dementia (CSDD) scale and the CES-
D73. Additionally, studies examining the validity of depression rating scales against 
the recently recommended criteria for depressive disorders in PD (see below) are 
needed 71.  
In general, the observer should score answers on the scales using an inclusive 
approach. When using rating scales, patients should be instructed not to attribute their 
symptoms to either PD or depression. Observers should choose an “inclusive 
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approach”, even if this potentially leads to higher scores. An exclusive approach may 
lead to an underestimation of depression severity. The experienced clinician should 
reflect on this problem. There are no sufficient instruments to identify minor or 
subsyndromal depression, recurrent brief depressive disorder or dysthymia which 
often occur in PD. The impact of age, cognitive impairment, apathy, and cultural 
differences on the validity of depression scales has to be studied further. 
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6. Aetiology of depression in PD 
6.1 Biological versus psychological explanations 
There is no complete understanding of the pathophysiology of depression in PD yet. 
Like de novo depression, depression in PD is a condition with heterogeneous etiology 
which can be explained on different physiological levels, molecular, genetic, cellular, 
and behavioural. Modern research often focuses only on one level, and a 
comprehensive understanding and evaluation of the growing evidence from genetic, 
pathological, pathobiochemical and imaging studies therefore becomes more and 
more difficult for the single researcher. 
Already James Parkinson stated in his original publication, that patients may become 
demoralized by the disease. Later on, Friedrich H. Lewy and Pierre Janet described 
an explicit association between PD and depression from a clinical view 48 74. At that 
time, depression was understood as a psychological reaction related to the trauma of 
having this neurological disease.  
At first sight, to react with depression seems understandable when suffering from a 
chronic, progressive, disabling disease, and the patients self often attribute their 
sadness to the disease. The high prevalence of depression especially in patients with 
early disease onset could be understood as the illness’ negative effect on their job 
situation, economic security and quality of life 75. If depression was solely determined 
by functional impairment, however, depression should become more common and 
more severe in later stages of the disease, i.e. the more severe the impairment, the 
more severe the depression. However, studies examining this relationship show 
conflicting evidence. Robins found that PD patients were much more depressed than 
chronically disabled control patients with an even more severe grade of physical 
handicap. And, within the PD group, depression was unaffected by the severity of the 
disability 76. Menza and Mark studied 104 patients with PD and 61 control subjects 
with equal disability scores, and found that PD patients were more depressed. 
Functional disability was correlated with depression and explained 9% of the 
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variance in depression. Depression was correlated with “harm avoidance” a 
personality trait related to central serotonergic systems but not with novelty seeking, 
a trait related to dopaminergic pleasure and reward systems. These results were 
discussed as support for the hypotheses that both physiologic and psychological 
factors contribute to depression in PD and that serotonergic dysfunction may be more 
important than dopaminergic pathways 77.  
Depression in PD and depression without PD have much in common. Depression as a 
rather homogenous psychopathological condition is unspecific regarding etiology. 
When treating the single case, it is difficult to attribute the patient’s depression to 
either ‘biology’ or ‘psychology’. Several studies have aimed to disentangle 
psychological and biological factors contributing to depression in PD. More of 
didactic reasons, researchers often construct their discussions around the dichotomy 
question: is it biology or psychology? However, it is more likely that a “mixed 
model”, which takes both pathophysiological changes associated with PD and 
psychosocial aspects into account, is more appropriate. Serra-Mestres and Ring 
showed that the pathophysiological changes in PD lead to an increased vulnerability 
to react to negative emotional stimuli with depression. Patients with more severe 
forms of PD and more prefrontal cognitive dysfunction are more vulnerable to the 
distracting effects of external negative stimuli. According to the cognitive model of 
depression, these patients are at high risk of developing clinical depression 78. 
Nilsson et al. showed in a large register study on more than 200 000 individuals, that 
PD patients had a higher risk of developing major depression compared with patients 
having other medical illnesses with a comparable degree of disability 79, suggesting 
that disease-related brain changes are more important than reaction to disability for 
the development of depression in PD. Cole et al. found depression to be related both 
to illness severity and functional impairment. The association was significant in men, 
but not in women and stronger in patients with early disease onset and those with 
right-sided PD; implicating that also biological alteration contributes 80. Brown et al. 
examined a sample of PD patients at two occasions. Depression and disability were 
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associated on both measure points. Depression was more severe in patients with a 
rapid disease progression and fast functional impairment and rather independent on 
the absolute change in disability 51. Schrag et al. found similarly results, i.e. higher 
depression scores associated with advancing disease severity, especially recent self-
reported deterioration, akinesia, occurrence of falls, self -reported cognitive 
impairment and the feeling of stigmatization. Therefore, treatment of depression 
should consider the patients' own perception of their disease 81.  
6.2 Pain and depression in PD 
Chronic pain, an unpleasant or distressing sensory experience, is a common, but often 
underreported problem in patients with PD 82. However, not all clinical descriptions 
of PD mention pain. In some patients, pain becomes severe enough to overshadow 
the motor symptoms of the disorder. Ford classified these painful sensations into 5 
categories: musculoskeletal pain, neuritic or radicular pain, dystonia-associated pain, 
primary or central pain, and akathitic discomfort. Additionally, there is a central pain 
syndrome, likely intrinsic to PD, however, its precise mechanism is unknown, and a 
correlation with pathology has not been made 83. When carefully questioned, more 
than half of all people with PD report painful symptoms and various forms of 
physical discomfort. In a large study on 450 PD patients, two thirds had chronic pain. 
26% had pain unrelated to PD ("non-PD-pain", caused mainly by osteoarthritis), 
while 39.3% had chronic pain related to PD ("PD-pain"). Parkinsonian patients with 
"PD-pain" were younger at PD onset, had more motor complications and more severe 
depressive symptoms 82.The patients may experience aching, stiffness, numbness and 
tingling at some point in the course of the illness. In another study, 269 (67%) of 388 
consecutive parkinsonian patients, presented sensory or painful syndromes 84. Among 
them, 94% had muscular pain, stiffness 85%, cramps, pseudo-cramps, spasms 3% and 
various myalgias 7%, 51% presented osteoligamentar "rheumatologic" pain. Restless 
legs or akathisia were also described (10%). Surprisingly, less defined and localized 
neurogenic painful syndromes, like paresthesia, dysesthesia, burning sensation and 
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itching were less frequent (8%). For some patients pain and discomfort are so severe 
that they overshadow the other problems caused by the disease. Since pain is known 
to contribute to depression in elderly people in general 85, it is likely that such an 
association also exists in patients with PD. However, very few studies have explored 
this hypothesis, and the available studies are based on small and selected samples and 
have reported inconsistent results 86 87.  Pain was among the major predictors of 
impaired quality of life in patients with PD 88. The complexity and pathophysiology 
of pain in PD still remains poorly understood. Thus, given the potential treatment 
implications, there is a need for further studies to explore the association between 
pain and depression in PD. 
6.3 Brain changes of depression in PD 
Patients who are later diagnosed with PD are more likely to have suffered from a 
previous depression than people who do not develop PD 89. This can only be 
explained by biological risk factors. These individuals do not know that they will get 
the disease, they do not suffer from disabling symptoms, thus, there is no 
psychological stress related to the disease yet. Therefore, in addition to being an 
understandable psychological reaction to the disease and functional impairment, 
depression in PD is probably also etiologically related to disease specific factors. 
Several of the brain lesions in PD have been discussed as potential contributors to 
depression in the general population. In the following, I will focus on some of these 
potential disease specific pathways, which have been explored in autopsy and 
imaging studies as well as genetic and cerebrospinal fluid studies. 
6.3.1 Serotonin 
Since the first studies into the pathophysiology of PD, the involvement of non-
dopaminergic neurotransmitter systems has repeatedly been described 90-93, reviewed 
by Leentjens 94. Serotonergic dysfunction is associated with idiopathic depression, 
although the relative importance for the etiology of depression is not yet clear. Given 
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the serotonergic model of depression 95, it seemed plausible to examine serotonergic 
mechanisms and their relationship to depression in PD as well. Mayeux and co-
workers were prompted to enunciate the “serotonin hypothesis” by their own finding 
of decreased concentrations of 5-hydroxyindolacetic acid (5-HIAA), a serotonin 
metabolite, in the cerebrospinal fluid of depressed PD patients 96. This finding was 
later replicated by Mayeux itself 47, while Kuhn et al. could not confirm it 97. 
However, several other neurochemical, neuropathological or imaging studies, in vivo 
or post-mortem supported the serotonergic theory.  
Depression has been reported to be associated with genetically polymorphisms, 
particularly of the serotonergic systems. Patients with the short allele of the serotonin 
transporter promotor scored significantly higher on both depression and anxiety 
measured by the Hamilton Depression and Anxiety Scales 98 99. Neurochemical 
involvement seems to vary between patients, depending on how much 
neurodegeneration has progressed in the relevant brain areas. More severe 
serotonergic neuronal cell loss in the dorsal raphé nucleus (DRN) was observed in PD 
patients with depression 100. Reduced echogenicity using transcranial sonography 
(TCS) in the mesencephalic raphé, also representing loss of serotonergic neurons and 
suggesting an involvement of the basal limbic system, was found to be associated 
with depression in PD 101. Using postmortem immunohistochemical analysis, 
Halliday et al. reported the first chemically identified loss of serotonin neurons in the 
median raphe nucleus of the pons and of substance P-containing preganglionic 
neurons in the dorsal motor vagal nucleus 102. It can be speculated, that such loss of 
serotonergic neurons may partly explain depression. 
11C WAY-100635 and PET reveals reduction in nucleus raphé 5-HT(1A) receptor 
binding in both depressed and non-depressed PD patients, but depressed patients have 
a greater reduction in cortical binding, reflecting post-synaptic 5-HT1A receptor 
dysfunction and supporting previous indirect evidence that serotonergic 
neurotransmission is decreased in PD 103. However, given the therapeutic potential of 
 30
manipulating serotonergic receptor systems, their relationship with depression in PD 
needs to be further explored. 
6.3.2 Noradrenalin 
Noradrenaline has been suggested to be associated with symptoms of idiopathic 
depression 104. The locus coeruleus is the major noradrenergic structure in the brain. 
From there, widespread noradrenergic neurons project to limbic areas and other 
regions. Greater degeneration within the locus coeruleus in depressed versus non-
depressed PD patients has been reported 105.  
Increased α1 and β1 receptors and decreased α2 receptors have been described in 
prefrontal cortex of demented and depressed PD patients and seem to be related to 
lesion of the noradrenergic pathways from the locus coeruleus to the cortex 106. 
Surprisingly, loss of neurons in the locus coeruleus was found in the caudal portion 
of the nucleus, which projects to the spinal cord. Remy et al. employed 11C-RTI-32 
PET to compare depressed with non-depressed PD patients 107. 11C-RTI-32 binds 
mainly to the dopamine transporter (DAT) in the striatum and a decrease of 11C-RTI-
32 binding reflects loss of catecholaminergic innervation in the corresponding 
regions of the brain. In this study, the depressed group had lower 11C-RTI-32 binding 
than the non-depressed group in the locus coeruleus and in several regions of the 
limbic system including the anterior cingulate cortex, the thalamus, the amygdala and 
the ventral striatum. The authors concluded that a specific loss of dopamine and 
noradrenaline innervations of the limbic system may be crucial for the etiology of 
depression in PD.   
6.3.3 Dopamine 
Depression has also been linked to the dopamine system, and one theory of 
depression in PD is the “dopaminergic” hypothesis which was introduced by Fibiger 
108. This theory was based on evidence from several studies indicating that the 
mesolimbic-mesocortical dopamine projections play an important role in reward and 
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reinforcement processes in both animals and humans. Fibiger linked the fact that 
mesolimbic and mesocortical dopamine projections degenerate in PD to the reduced 
ability to experience pleasure or reward (i.e. anhedonia) as cardinal features of PD 
and suggested that damage to these reward-related systems may contribute directly to 
the high incidence of depression in PD 108. 
In the earliest stages of the disease, before the onset of motor symptoms, 
mesocortical, and mesolimbic dopaminergic pathways are also affected 109. These 
projections mediate self reward mechanisms, and damages here result in a reduced 
ability to experience pleasure or reward (i.e. anhedonia), a core symptom of 
depression. 
Both serotonergic and cholinergic systems have an inhibitory effect on dopamine, 
and a reduction in the activity of serotonergic and cholinergic systems can 
compensate the dopaminergic lesions initially. However, subsequently, cholinergic 
and noradrenergic neurons begin to degenerate, albeit to a less extent. These 
processes may be relevant for the development of depression and may also explain 
why depression often precedes the motor symptoms. 
The limbic system with its nuclei and connections is a crucial anatomical substrate 
for emotions. These limbic centres and nuclei are supplied with dopaminergic 
innervation arising from the ventral tegmental area (field A10). In PD there is 
variable loss of dopaminergic neurons in the ventral tegmental area (VTA) 110, thus, 
the connections with the limbic system and also the orbitofrontal cortex are interfered 
111. Winter et al. tested the influence of dopaminergic systems and their 
interrelationship with serotonergic systems in depressionlike behavior in a rodent 
model. Lesions in the substantia nigra pars compacta (SNc) and VTA increased 
depressive-like behavior in rats. Both citalopram and l-Dopa could reduce such 
behavior 112. This suggests a direct involvement of dopaminergic lesions of either the 
SNc or the VTA but also serotonergic pathways in dopaminergic cell loss-induced 
depression.  
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Tyrosine hydroxylase (TH) is the enzyme responsible for catalyzing the conversion 
of the amino acid L-tyrosine to DOPA. DOPA is a precursor for dopamine which in 
turn is a precursor for noradrenaline. The nigrostriatal loss of TH, dopamine and 
dopaminergic neurons in PD lead to changes, which may also directly or indirectly 
damage the forebrain catecholamine fibers and induce depression.  
The reported efficacy of dopamine agonists, especially pramipexole, against 
depression in PD (see below under management) also support the dopaminergic 
hypothesis.  
6.3.4 Acetylcholine 
Evidence from epidemiological 25 and pathophysiological studies 113 114 suggest a 
relationship between depression and dementia in PD. In longitudinal studies, 
depressed PD patients had greater cognitive decline compared with non-depressed 
patients 45 115. Depression in PD is associated with a quantitative but not qualitative 
worsening of cognitive deficits 116. This suggests that a common mechanism might 
underlie both the affective and the cognitive disturbances. Bohnen et al. reported in 
vivo findings suggesting that cholinergic degeneration may play a significant role in 
the cognitive decline in PD 117. Therefore, the same group raised the question whether 
also depression is, at least in part, associated with cholinergic hypofunction. In 
dynamic PET studies, applying the [11C]methyl-4-piperidinyl propionate (PMP) 
radioligand, a selective substrate for AChE hydrolysis, an association between 
depressive symptoms and cortical cholinergic denervation was found, even after 
controlling for cognitive impairment 118. 
If depression was a risk factor for dementia, two theoretical explanations for this are 
(1) the comorbid mood disorder is an expression of more widespread 
neurodegeneration, or (2) the treatment used for the depression contributes to the 
pathological process leading to dementia.  Regarding the latter, tricyclic 
antidepressants with their anticholinergic properties may influence cognition both due 
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to the cholinergic blockade, which is associated both with cognition and depression 
in PD 118, but also with an accumulation of Alzheimer-like pathology 119.  
Loss of cholinergic neurons occurs early in PD, and is considered to be a key factor 
in the development of dementia in PD 120. Not surprisingly therefore, there is 
evidence from clinical studies that use of anticholinergic drugs is a risk factor for 
dementia in the general population 121 and worsening cognition in people with 
dementia 122 123, but very few studies exist in PD. Preliminary data from a small cross-
sectional study indicate such an effect in PD 124. This is consistent with findings that 
PD patients who had received long-term treatment with anticholinergic drugs had 
significantly higher cortical plaque and tangle densities compared to patients either 
untreated or receiving only short-term treatment 119.  Prospective, longitudinal studies 
are needed to explore the hypothesis that tricyclic antidepressants and other drugs 
with anticholinergic activity contribute to cognitive decline in PD. This is of 
particular relevance given the recent trial suggesting that nortriptyline is effective for 
depression in PD 125. 
6.4 Structural and functional imaging  
The recent development of a range of novel imaging technologies have contributed 
importantly to the investigation of brain changes associated with clinical symptoms in 
PD. To image the many structural and neurochemical changes in PD means either 
mapping alterations in brain structure or function. MRI can reveal structural changes 
like volume reductions. Functional imaging (Positron Emission Tomography - PET, 
single-photon emission CT [SPECT], functional MRI, and proton magnetic 
resonance spectroscopy) is applied to detect and characterize regional changes in 
brain blood flow, metabolism, and receptor availability or binding 126. Structural MRI 
studies have demonstrated an association between regional atrophy and dementia 127 
and mild cognitive impairment 128 (Beyer), but have not yet contributed to the brain 
changes underlying depression in PD.  
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Experimental studies have shown that diffusion tensor MRI (DTI) may contribute to 
the early diagnosis of Parkinson's disease (PD) and that fractional anisotropy (FA) 
and apparent diffusion coefficient (ADC) values on DTI in the basal ganglia and 
frontal areas are different in PD patients compared with healthy controls 129. In a 
study comparing PD patients with and without depression, the depressed subjects 
showed significant reductions in FA values in the bilateral anterior cingulate bundles 
130. 
As mentioned above, Lewy body pathology can affect the serotonergic cells in the 
median raphe 13. However, a positron emission tomography study using 123I-beta-
CIT SPECT failed to show a relationship between serotonergic median raphe HT1A 
binding or brainstem serotonin transporter (SERT) binding and the presence of 
depression in PD 131 . The finding of reduced frontal 5-HT1A binding in PD patients  
with depression is consistent with previous reports from Mayberg et al. who, using 
PET studies,  found regional cerebral glucose metabolism reduced in depressed 
compared with nondepressed patients with PD 132. The authors suggested that 
depression in PD is associated with dysfunction in the caudate and orbital-inferior 
area of the frontal lobe and that disruption of basal ganglia circuits involving the 
inferior region of the frontal lobe may affect the regulation of mood.  
Studies using transcranial sonography (TCS) have provided evidence of alterations in 
the mesencephalic midline structures in patients with unipolar depression and 
depression in Parkinson's disease (PD). Berg et al. examined 31 PD patients with 
MRI and transcranial sonography (TCS).  A significant reduction in mesencephalic 
midline echogenicity of depressed compared to nondepressed PD patients was 
detected on TCS images 101. Brainstem midline structures comprise fiber tracts and 
nuclei of the basal limbic system. Following this, the authors interpreted their finding 
as supporting the hypothesis that the basal limbic system is involved in mood 
disorders in PD. 
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7. Management of depression in PD 
 
During the last three decades, several new treatment options for the management of 
depression were described. Novel psychosocial, psychotherapeutic and 
pharmacologic strategies have significantly transformed the choice of treatment of the 
depressive patient.  Similarly, since the introduction of  “first-generation” 
antidepressants, the tricyclic drugs and monoamine oxidase inhibitors, the number of 
different antidepressant drugs has grown dramatically. Newer classes of drugs 
include the selective serotonin reuptake inhibitors (SSRI), serotonin-noradrenalin 
reuptake inhibitors (SNRI), dopamine-noradrenalin reuptake inhibitors, serotonin 
modulators, noradrenalin-serotonin modulators, and selective noradrenalin reuptake 
inhibitors (NRI). Compared with traditional antidepressant drugs, newer drug classes 
such as SSRIs and SNRIs offer improved tolerability to therapy with a high level of 
efficacy. But all antidepressants produce unwanted effects including drowsiness, dry 
mouth and urinary retention and cardiac arrhythmias, gastro-intestinal upset and 
others, especially in the elderly patient with comorbid conditions such as PD. The 
choice of an antidepressant is guided not only by its efficacy, but should also take 
into consideration safety and potential side effects.  
However, in patients with PD and depression, the choice of treatment is difficult due 
to the limited empirical evidence to support treatment strategies. This was highlighted 
in a Cochrane review in 2003 133. Although some evidence was added since then, 
there is still limited evidence available. 
Depressive symptoms in PD often remain undiagnosed and untreated. In one study, 
37% of subjects with PD receiving an antidepressant still met criteria for Major 
depression, thus, even when delivered; treatment is often inadequate or ineffective 39. 
Furthermore, psychosocial support or psychotherapy was not provided to patients not 
responding on pharmacotherapy. There are several possible explanations for this 
situation, including poor cooperation with psychiatric services, misinterpretation of 
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symptoms or ignorance toward psychiatric symptoms. Moreover, the lack of evidence 
of treatment strategies may result in a kind of nihilism in the face of depression in 
PD. In the following, the existing evidence on treatment of depression in PD is 
reviewed. 
7.1 Psychosocial and psychotherapeutic strategies 
Very few systematic studies have explored the effect psychosocial treatment 
strategies on the development or treatment of depression in PD. During the course of 
PD, many patients with PD become dependent from care. Dealing with the negative 
consequences of PD and managing the functional impairment, especially in late 
stages of the disease, is important and might reduce the risk for depression in some 
patients. Negative consequences of the disease, such as difficulty in dressing, 
difficulty turning, falls, autonomic disturbance particularly urinary incontinence have 
been found to be associated with depression and predict poor quality of life 88. An 
association between lack of social support and depression has been found in elderly 
people 134. Sufficient social support is an effective buffer against stress related to 
suffering. Cheng et al. investigated the correlation of social support, measured by a 
standardized scale, with depression in PD and corrected for potential confounding 
factors such as disease severity and duration. Unfortunately, ‘social support’ was not 
defined in detail, but both subjective experience and objective circumstances were 
considered. The results suggest that adequate social support may improve depression 
135. ‘Social support’ can probably be provided by professional and informal 
caregivers such as family or friends. Whether Cognitive Behavioral Therapy (CBT) is 
effective against depression in people with this complex degenerative condition is 
still an open question. The available evidence is not strong, but we assume that the 
efficacy literature of psychotherapies in older adults with other chronic diseases also 
applies to the PD population 136. Patients with PD and depression are a vulnerable, 
often neglected group. This would appear to provide a sound clinical basis to attempt 
to confirm the validity of CBT in this population 137.  
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7.2 Pharmacotherapy 
 
A review on the treatment of depression published by the Quality Standards 
Subcommittee of the American Academy of Neurology  in 2006 identified 36 studies, 
of which only 6 studies fulfilled the defined criteria of study design and outcome 
measures 138. Only one study qualified for Class I evidence (randomized, doubleblind, 
placebo-controlled) 139, two studies for Class II 140 141 and three for Class III evidence 
142-144. All were randomized controlled trials, and included amitriptyline, 
nortriptyline, citalopram, fluoxetine, sertraline, pergolide, pramipexole, and 
nefazodone. Three of the studies used placebo comparators. No significant benefit of 
citalopram or sertraline was found over placebo, but lack of benefit was maybe 
related to methodological limitations 139 141. Fluoxetine and nefazodone revealed 
equal efficacy for depression, but this study was not placebo-controlled, and thus, one 
cannot conclude whether either drug was effective 144. Patients treated with 
pramipexole improved significantly more than patients treated with pergolide on 
measures assessing depression 143. In a study comparing amitriptyline with fluoxetine, 
patients randomized to amitriptyline significantly improved (change in HAM-D of 
14), while those treated with fluoxetine did not 142. However, dropout rates were 
greater in the amitriptyline group due to side effects. In an early study of 
nortriptyline, the authors report a significant improvement in depression compared to 
placebo 140. However, it is impossible from the publication to determine if this 
difference was significant. After discussion of the strengths and limitations of the 
most relevant trials, it was concluded, that “there is insufficient evidence to make 
recommendations regarding treatments for depression in PD” 138.  
Weintraub et al. reviewed the available antidepressant studies in PD 145. Relevant 
studies were analyzed and effect sizes were compared with those from antidepressant 
studies in elderly patients without PD. While active treatment in general was superior 
to placebo in depressed elderly patients without PD, this was not the case in PD. 
However, both active treatment and placebo had large effect sizes in PD. 
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Traditionally, effect size or Cohen’s d index is the difference between patient and 
control group means, within each study or comparison, expressed in standard 
deviation units. Weintraub et al. used “effect size” as the change from baseline for 
each study. This large placebo effect was also shown in two of the very few 
adequately designed placebo-controlled randomized trials with SSRI in depressed PD 
patients 139 141. Old age and a diagnosis of major depression seem to be associated 
with a better response to any antidepressant treatment. Newer antidepressants are well 
tolerated in PD. The repeated observation that SSRIs is less effective for depression 
in PD than in non-PD patients is used as an argument against an exclusive 
serotonergic hypothesis of depression in PD 145. 
A recent placebo-controlled trial, funded by the US National Institute of Health, 
compared nortriptyline up to 75 mg, paroxetine CR up to 37,5 mg, and placebo in 
patients with PD and depression 146. Although the largest study in this population, 
even this trial is small by clinical trial standards. Efficacy was assessed by the change 
in HAM-D. Compared to placebo, the treatment effect of nortriptyline was significant 
for both the overall change in the HAM-D and in the percentage of responders, while 
that of paroxetine CR was not. The effect size of nortriptyline was large (1.20, based 
on HAM-D) and the number needed to treat for nortriptyline was 3.5 based on 
response status. In addition, nortriptyline improved social functioning, sleep, and 
anxiety. Patients on paroxetine CR had significantly more side effects than placebo, 
but those on nortriptyline did not, although both drugs were well tolerated. 
Nortriptyline acts as a dual reuptake inhibitor, inhibiting reuptake of both serotonin 
and noradrenalin, whereas paroxetine CR is a selective serotonin re-uptake inhibitor. 
These results provide additional evidence to the theory that the noradrenergic system 
is involved in depression in PD 107, and the authors speculate that the noradrenalin 
transporters may play a role. The noradrenalin reuptake transporter is responsible for 
removing dopamine from the synapse in the prefrontal cortex. If these transporters 
are blocked by nortriptyline, dopamine levels can increase, facilitating dopaminergic 
function. Until now, SSRI has been the first line choice for depression in PD. The 
results of this trial suggest a re-evaluation of this clinical practice.  
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Dopamine agonists, especially pramipexole, have shown anxiolytic, antidepressive 
and antianhedonic effects in experimental and clinical investigations 147-150. These 
effects are likely related to dopamine agonists having specific action on D(2) and 
D(3) receptors in the mesolimbic system and prefrontal cortex 151. Recently, 
pramipexole was even recommended as a first-line treatment in patients with PD and 
depression 152. Treatment with dopaminergic drugs does not, however, consistently 
alleviate depression in PD 153 
7.3 Biological, non-pharmacological agents 
7.3.1 Electroconvulsive therapy 
Electroconvulsive therapy (ECT) is the most effective treatment of idiopathic major 
depression and has been recommended for treatment of both depression and motor 
symptoms in PD. Faber and Trimble reviewed 27 studies published until 1991 and 
concluded that approximately 70% of PD patients showed improvement in 
psychiatric disturbances (including depression) across the  studies reviewed 154. Only 
one of the 27 was a controlled study, which included 11 patients with PD but without 
psychiatric co-morbidity. The majority of studies were single case reports and none 
of the other studies included more than 7 patients. In a retrospective chart review 
Moellentine et al. studied 25 patients with PD receiving ECT for psychiatric co-
morbidity (major depression with and without psychosis, anxiety disorder and 
dementia). The results were compared with those of 25 patients without a comorbid 
neurological condition 155. In this study, ECT improved depression, anxiety, cognitive 
status and overall global functioning in both groups. In addition, motor functions 
were improved in 56% of the PD patients. However, 56% of the PD patients 
experienced complications compared to only 12% in the comparison group. The 
positive response to ECT in PD is often rapid 156 157 but may be short-lived. However, 
maintenance ECT may contribute to a sustained effect 158. Transitory cognitive 
worsening is the most common side-effect, and some patients may experience 
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delirium, urinary retention, choreiform movements, and falling 155 159 160. The precise 
mechanism of action of ECT on both depression and motor symptoms is unknown; 
one hypothesis is that ECT stimulates different neurotransmitter systems, including 
the D2 receptor. The seizures induced by ECT can increase both noradrenaline and 
serotonin levels in the brain 161. Noradrenaline increases dopamine levels in the basal 
ganglia which may explain the positive effects on motor function 162. 
7.3.2 Transcranial magnetic stimulation 
Repetitive transcranial magnetic stimulation (rTMS) of the cerebral cortex has shown 
some antidepressive effect in treatment resistant patients with idiopathic depression 
163. RTMS has also been suggested as a potential treatment option for both depression 
and the movement disorder in PD. Cardoso et al. compared the neural changes after 
successful therapy of depression in PD with TMS with the changes after successful 
treatment with fluoxetine by event-related functional magnetic resonance imaging 
(fMRI) methods 164. 
Both rTMS and fluoxetine had a significant, similar mood improvement. Reduction 
of depressive symptoms was related to reduced activity in selected brain areas after 
rTMS, whereas increases were found in other areas after fluoxetine treatment, leading 
the authors to conclude that antidepressant effects of rTMS and fluoxetine in PD are 
associated with changes in different areas of the depression-related neural network. 
 
7.3.3 Deep brain stimulation  
During the last 20 years, deep brain stimulation (DBS) of selected nuclei such as 
subthalamic or thalamus, has become established as a safe and efficacious treatment 
option in movement disorders 165. Indications for DBS are PD, essential tremor and 
dystonia. Case reports suggest that major depression and also obsessive-compulsive 
disorder may respond to DBS 166. On the other side, depression, hallucinations, 
cognitive impairment, mania, and behaviour change were reported as side effects 
after DBS 166. Particularly thalamic and GPi stimulation may cause suicidal 
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behaviour. Therefore, patients should be monitored cautiously for suicidal thoughts 
pre- and post-operatively. 
In summary, until recently the evidence for treating depression in PD has been very 
limited. The recent study suggesting that nortriptyline is effective is encouraging, 
however, but the findings need to be confirmed in larger studies. Although other 
treatment, such as ECT and psychotherapy, may be helpful for some patients, the 
evidence is still very limited.  
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8. This study 
8.1 Aims of this study 
The overall aim of this project is to explore key aspects of depression in PD where 
there is currently limited knowledge, including epidemiology, clinical profile, 
classification, aetiology and treatment-related factors. To obtain such information we 
have 
1) In study 1 performed a systematic review of available epidemiological data 
and explored the frequency of depression in PD 
2) In study 2 explored the symptom profile of depression in PD, testing the 
hypothesis that depression in PD differs from that in elderly depressed people 
without PD  
3) In study 3 explored depressive symptoms in patients with PD without major 
depression, i.e. sub-threshold depression, and examined its relationship to 
other clinical features in PD. 
4) In study 4 examined the relationship between pain and depression in PD, 
testing the hypothesis that pain is significantly associated with depression in 
PD.  
5) In study 5 examined the relationship between the serotonin systems in 
different brain areas with depression, testing the hypothesis that depression in 
PD is related to changes in 5HT1a receptors in neocortical regions. 
6) In study 6 explored the use of drugs with anticholinergic properties in patients 
with PD to test the hypothesis that treatment with tricyclic antidepressants and 
other drugs with anticholinergic activity is associated with a more rapid 
cognitive decline.  
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8.2 Methods 
8.2.1 Design  
The present studies are parts of a research programme on different aspects of PD, 
consisting of a sequence or combination of overlapping studies with different study 
designs. Cross-sectional survey was used for studies 2 and 3. Studies 4 and 6 were 
longitudinal cohort studies. Study 1 was a systematic review and Study 5 a clinical-
pathological study. 
8.2.2 Methods for the systematic review 
A systematic literature search was carried out in Medline using PubMed. The entire 
time scale was used up to February 2007. Key words were “Parkinson”, “depression,” 
“prevalence”, and “incidence.” In total 272 articles were retrieved. After exclusion of 
papers with limited methods, 104 articles were included and underwent quality 
assessment. The included articles were read in full and quality rated by three of the 
authors Jennifer Reijnders, Uwe Ehrt and Dag Aarsland. When the raters could not 
agree on a rating, consensus was achieved after discussion. If consensus was not 
reached, articles were reassessed by the last author Albert Leentjens who made a final 
decision. The quality assessment used criteria adapted from Aarsland et al. 167. 
8.2.3 Patient selection 
Several different patient and control samples were used for this thesis. Most studies 
were fully or in part based on a community-based prevalence sample, sample 1.  In 
September 1992 a prevalence study was initialized with the aim to detect all patients 
with PD in Rogaland County, Western Norway. Information from general 
practitioners, nursing homes, district nurses, health workers and the Rogaland 
Parkinson’s Society was collected, and an extensive search in relevant hospital files 
was performed to achieve complete ascertainment of patients with PD in this region. 
About 400 patients with symptoms suspect for PD were systematically registered and 
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examined by neurologists, who were proficient in diagnosing and treating movement 
disorders. In the first instance, 245 out of the 400 were diagnosed with PD according 
to clinical criteria published by Larsen et al. 2. The total crude and age-adjusted PD 
prevalence rates were calculated to be 110.9/100 000 and 102.4/100 000, respectively 
168. As part of this study, 100 healthy elderly people were randomly selected and 
represent a healthy control group. 
The patients included were examined with a standardized examination program in 
1993, 1997, 2001 and yearly after 2001. In this study we used only data from the first 
three assessment points. During follow up, 6 patients were re-diagnosed as not 
suffering from idiopathic PD and therefore excluded from analysis. From some 
patients, we could not collect complete data at follow up. Those had to be excluded 
from some but not all of the longitudinal studies. 
Study 4 and 6 are exclusively based on Sample 1, and Study 4 also included the 
healthy control group. In other studies, we included control groups or included data 
from other collaborating research centres. The 111 PD patients of the subsample from 
The Netherlands in study 2 were recruited from the neurological outpatient 
department in Maastricht and were assessed between 1995 and 2001. A comparison 
group consisting of 100 consecutively patients referred to the Old Age Psychiatry 
outpatient clinic at Stavanger University Hospital, Norway suffering from at least 
mild depressive symptoms with a MADRS score 7, were also included. In study 3, 
Patients were recruited from research centres in 11 European countries and Canada to 
participate in a multicentre trial of rivastigmine for Parkinson’s disease Dementia 
(PDD).  
8.2.4 Diagnosis and rating of PD 
In sample 1, PD was diagnosed by neurologists with special expertise in movement 
disorders according to criteria published by Larsen et al. 2. Until now, 27 of the total 
PD population have come to autopsy, and the diagnosis of PD was confirmed 
neuropathologically in all cases 169 (R. Perry, personal communication). The PD 
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patients of the Dutch sample from study 2 and the patients from study 3 were 
diagnosed on the basis of the UK-Parkinson’s Disease Society Brain Bank (UK-PDS-
BB) criteria 170. The clinical examination of motor symptoms consisted of a complete 
Unified Parkinson’s Disease Rating Scale (UPDRS) 5 and the Hoehn and Yahr 
disease staging 171. Based on the UPDRS subscores, tremor-dominant (TD), akinetic-
rigid (AR) and indifferent motor subtypes were defined, following procedures used in 
previous studies 172. Furthermore, right and left side motor subscores were computed 
according to procedures published before, by adding the respective scores for right 
and left-sided motor symptoms on UPDRS items 20–26  31. These clinical subtypes 
were used in some analyses in studies 3 and 4. 
8.2.5 Diagnosis and rating of depression 
Depression was rated in sample 1 by a neurologist using the MADRS 173 and the  
Beck Depression Inventory (BDI) 174. The MADRS was originally designed as an 
instrument, which should be particularly sensitive to psychopathological change 
resulting from drug treatment 173. The ten items (apparent and reported sadness, inner 
tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability 
to feel, depressive and suicidal thoughts) are completed during a clinical interview. 
The clinician first asks broadly phrased questions about the topic of the item and 
afterwards more detailed ones which allow a precise severity rating (from 0-6). High 
inter-rater reliability was reported in several studies. Studies gave the impression that 
the MADRS performed comparably or even better than HADS or HRDS, in terms of 
general validity and reliability 175 12457. The MADRS focuses mainly on psychic and 
less on somatic symptoms compared with several other scales, which is an advantage 
in settings where physically ill patients are assessed. 
The BDI is a 21-question multiple-choice self-report inventory, one of the most 
widely used instruments for assessing presence and severity of depression, especially 
in a scientific context. The 21 items of the BDI intend to cover depressive symptoms 
in line with DSM-IV criteria. Each question has a set of at least four possible answer 
choices, ranging in intensity. For example: (0) I do not feel sad; (1) I feel sad; (2) I 
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am sad all the time and I can't snap out of it; (3) I am so sad or unhappy that I can't 
stand it. When the item is scored, a value of 0 to 3 is assigned for each answer and 
then the total score determines the severity of depression.  
The BDI has a relatively broad coverage of the somatic symptoms of depression, 
which may lead to false-positive results among persons with physical illness. 
However, as described above, in our study we used cut-offs validated in PD patients 
which should reduce this concern. 
Both instruments have been shown to be valid depression scales in patients with PD, 
and cut off scores are available to identify depressive disorders according to DSM IV 
criteria 176 177. MADRS scores 18 and BDI scores 17 indicate the presence of major 
depression with relatively high specificity.  
The MADRS was also used as rating scale for depression in the subsample from our 
collaboration centre in The Netherlands (study 2).  
The patients from study 3 had no major depression according to exclusion criteria. To 
assess depression, item 4 of the 10-item Neuropsychiatric Inventory (NPI) was used 
178. The NPI addresses ten specific psychopathological, noncognitive domains, 
among them depression. Regarding depression, a positive answer on the introducing 
question “if the patient seems to be depressed or says that she/he is depressed” is the 
precondition to ask further. Then follow several questions focusing exclusively on the 
mood symptoms of depression. Does the patient often cry? Is he suffering from 
feelings of guilt, hopelessness, and suicidal ideas and so on. Finally, an informant 
rates the severity of depression on a scale from 1–3 and the frequency of depression 
from 1–4. A composite score is the product of frequency and severity, yielding a 
score ranging from 1–12. A score of 4 or higher is usually considered to represent 
clinically significant severity of symptoms.  
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8.2.6 Diagnosis of dementia and cognitive assessment 
Cognition was assessed by means of the Mini Mental State Examination (MMSE) 
scores 179 and in study 3 additionally with the Alzheimer’s Disease Assessment 
Scale––cognitive subscale (ADAS–cog) 180. These are cognitive screening tests 
designed primarily to assess cognitive decline in patients with Alzheimer’s disease, 
but in particular the MMSE has also frequently been used for PD. The scales focus on 
memory, language, praxis, attention and other cognitive abilities. High scores 
represent high cognitive functioning on the MMSE and low performance on the 
ADAS. 
8.2.7 Techniques used to study brain tissue  
Post-mortem brain tissue was obtained from 27 patients with dementia and 
parkinsonism, consisting of 10 patients with dementia with Lewy bodies (DLB) from 
the Newcastle (UK) dementia case register study 181 and 17 PDD patients from 
sample 1, along with 9 controls. Coronal brain slices were flash frozen in liquid 
nitrogen before being stored at – 70 °C. Inferior (Brodmann area, BA20) and superior 
(BA36) temporal cortices were removed. Brain membranes were prepared 182 and 
binding of [3 H]8-hydroxy-2- ipropylaminotetralin (8-OH-DPAT) to the 5-HT1A  
receptor was performed following the methodology previously described 183.  
8.3 Results  
8.3.1 Study 1 
We identified 104 relevant studies, 22 studies focused primarily on the prevalence of 
depression in PD; the remaining 82 studies had other primary objectives but also 
reported on the prevalence of depression in the study sample. There were 16 
population-based studies, 3 studies in general practices, 2 studies in nursing homes, 
71 studies on outpatient samples, 5 studies in hospital inpatient settings and 7 studies 
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used patients from  different settings. Different diagnostic criteria for depression were 
used: 31 studies used a structured or semistructured interview to establish DSM 
criteria, 20 studies used DSM criteria without a structured interview, 38 studies used 
a cut-off score on a depression rating scale, and 15 studies used no or inadequate 
criteria to diagnose depression.  
Of the 104 studies, 51 fulfilled our operationalized quality criteria and were included. 
After excluding studies based on the same, cumulative or joint databases, 36 studies 
were included in the review. Overall, major depressive disorder was present in 17% 
of patients, minor depression in 22%, and dysthymia in 13%. The prevalence of 
clinically significant depressive symptoms was 35%. For major depressive disorder, 
population studies report significantly lower prevalence rates than studies in 
outpatient samples and hospital inpatient settings. The reported prevalence of major 
depressive disorder in studies using a structured or semi structured interview to 
establish DSM criteria ranges from 2.3% to 55.6% with a weighted mean of 19%. In 
studies using DSM criteria without a structured interview the prevalence rates of 
major depressive disorder ranges from 2.9% to 7.7% with a weighted mean of 7%. In 
studies using a cut-off on a depression rating scale, the rates were higher, between 
13% and 89% with a weighted mean of 42%.  
8.3.2 Study 2 
One hundred and forty-five patients with PD, 76 cases from sample 1 and 69 cases 
from our collaboration group in Maastricht, The Netherlands, fulfilled the inclusion 
criteria. The depressed comparison subjects without PD were older than the patients 
with PD, but did not differ significantly for sex distribution, MMSE score and total 
MADRS score. The comparison subjects had MD (mild, moderate or severe), some 
of them were at time of assessment in partial remission. Fourteen patients with PD in 
the Stavanger group (18.4%) received antidepressants (13.2% a TCA, and 5.2% 
mianserine), whereas 83% of the controls took antidepressants (45% an SSRI, 24% 
mianserine, 13% TCA, 2% lithium, and 25% other antidepressants). Medication data 
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were not available for the Maastricht cohort. PD patients or control subjects who 
received antidepressant medication differed significantly from subjects not receiving 
antidepressants with respect to gender distribution, age, MMSE score, and MADRS 
single item and sum scores. All MADRS sub items were significantly correlated with 
the sum score in both PD and non-PD patients (Pearson coefficient r range 0.26–0.79, 
all p-values <0.005). 43.5% of the Maastricht sample fulfilled MD criteria, compared 
to 10.5% of the Stavanger patients with PD (taken together 26.2%). Since the patients 
from Maastricht were more depressed, we formulated a model with study site as 
covariate (MANCOVA). The omnibus analysis showed significant greater between-
group than within-group differences regarding the MADRS score profile In this 
model patients with PD had less reported sadness, slightly less loss of energy,, more 
concentration problems, less feelings of guilt and lower score on item 8, disturbed 
affective reactivity (anhedonia). 
8.3.3 Study 3 
Depression item on the NPI was assessed in 538 patients (35% females) and these 
were included in the study. 116 patients (21.6%) had a NPI depression score 4 
indicating clinically relevant depressive symptomatology, and constituted group with 
PD related dementia and depression. Depressed patients were more likely to be 
female (p=0.025), and were younger both at onset of PD (p=0.017) and at assessment 
(p=0.003) than non-depressed patients. They were more likely to receive 
antidepressants (41.4% vs. 22.5%; p<0.0001) and benzodiazepines (27.6% vs 17.3%; 
p=0.011) than non-depressed patients. Since female patients were more depressed 
than male patients, clinical correlates of depression were explored in male and female 
patients separately. There were no significant gender differences regarding age, age at 
onset, PD duration, UPDRS score, Hoehn and Yahr stage and NPI total score. 
However, male patients performed better on cognitive rating scales than female 
patients as demonstrated on the ADAScog score [mean 22.8 (SD 10.0) vs 25.5 (SD 
10,5); t=2.852; p<0.005] and MMSE [sum score 19.6 (SD 3.9) vs. 18.7 (SD 3.6); 
t=2.585; p<0.01]. The association between depression and younger age both at 
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assessment and at onset of PD was confirmed in male (p<0.01) but did not hold true 
for female (p=0.397) patients. Similarly, males with left-sided parkinsonism scored 
higher on depression than those with right-sided PD [NPI item 4 score 1.99; SD 2.57 
vs. 1.16; SD 1.92 (p=0.014)], whereas no difference between right- and left-sided PD 
was found in females (p=0.23).  
8.3.4 Study 4 
152 (67%) of the 227 included PD patients vs. 39% of the comparison subjects 
suffered from pain as assessed by the Nottingham Health Profile (p<0.001). PD 
patients with pain had more severe depressive symptoms, indicated by higher mean 
scores on both MADRS and BDI. Patients with pain and also had more severe motor 
symptoms, longer disease duration, and lower MMSE score than those without pain. 
No significant differences were found regarding sex distribution, age and use of 
analgesics. Even after adjustment for potential confounders, pain was significantly 
associated with BDI.  
Both the MADRS (p<0.00001) and BDI sum score (p<0.0005) correlated 
significantly with pain. Multiple linear regression analyses with BDI and MADRS as 
dependent variables were significant even after adjusting for sex, age, PD duration, 
UPDRS III score and MMSE score. The effect of pain severity (partial correlation 
with depression severity) was significant in the model with MADRS (p=0.014) and a 
trend in the model with BDI (p=0.056). 
Compared to patients with a tremor-dominant (TD) subtype, patients with an 
akinetic-rigid (AR) type more commonly reported pain (72 % vs. 48%; p=0.002). AR 
patients also had more severe depression according to MADRS sum score than TD 
patients (p<0.0001).  
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8.3.5 Study 5 
67% (n=18) of the DLB/PDD patients had experienced clinically significant 
depression over the course of the illness (4 DLB, 14 PDD). 5HT1A density was 60% 
higher in BA36 in combined DLB/PDD patients with depression, compared to those 
without. This difference was significant (p=0.005).  Subgroup analyses were 
hampered by the small sample sizes, but  in the PDD group, 5- HT 1A density was 
significantly higher in BA36 in those with depression compared to the small number 
of patients without (p = 0.042). We could not detect a significant difference in 5-HT 
1A density or affinity in either BA20 or BA36 between DLB subjects who had 
experienced depression during the course of the disease and subjects who had not.  
8.3.6 Study 6 
The 235 PD patients used a total of 99 drugs, and 29 of these drugs were classified as 
having clinical relevant anticholinergic activity (AA). At baseline, 102 of the 235 
patients (43.4 %) received at least one drug with AA. The most frequently used drugs 
with AA were antidepressants (n=84), cardiovascular agents (n=80), anxiolytics and 
sedatives (n=61), and antipsychotics (n=44). Seventy-two subjects (30.6%) were 
taking more than one drug with AA. At baseline, patients taking AA agents had 
significantly lower cognition (MMSE median 25) and higher depression scores 
(MADRS median 9) than those not taking AA agents (28 and 6, respectively). Total 
AA load correlated significantly with MMSE (Spearman rho=-0.205, p=0.002) and 
MADRS (Spearman rho = 0.321, p<0.001). Using linear regression analysis, after 
adjusting for age and gender, MADRS (standardized beta 0.291, p<0.001) but not 
MMSE score remained significantly associated with the AA load in a linear 
regression analysis. In longitudinal analyses, the median change in MMSE over the 
full 8-year period in subjects who had used AA drugs at some point (n=62) was 8 
points (IQR 16), whereas those who had not used AA drugs at any assessment 
(n=22), declined only 1 point (IQR 6.75). This difference was significant (Mann 
Whitney test z=-2.3, p=0.021). The correlation between total AA load during the 8 
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years (ie sum of AA load at all three assessments) and the change in MMSE score 
was significant (Spearman rho=0.26, p=0.017). In the linear regression analysis, after 
adjustment for potential confounders, the association between AA load and MMSE 
decline remained significant (Beta 0.154, SE 0.072, standardised Beta=0.217, 
p=0.036; total model F=5.4, p<0.001).  
8.4 Discussion 
8.4.1 Methodological critique 
The primary goal of epidemiological research is to provide evidence on the incidence, 
prevalence and progression of diseases, and to find associations with risk factors in 
the population. For example, linkages between smoking and lung cancer or heart 
disease and the consumption of certain fats were found by epidemiological research. 
The careful interpretation of such data is the basis for the establishment of causality, 
and thus, a precondition for identifying groups at high risk or the development of 
both prevention and treatment strategies. Epidemiological data on the highest level of 
quality represent the general population. However, for several reasons, including 
resources, the researcher may have to lower one’s ambitions and employ alternative 
methods. Such limitations may involve the patient selection and completeness of 
case-ascertainment, but also the case definition and diagnostic accuracy and methods 
of measurement. In the following I aim to mark some basic methodological topics 
and discuss critically the specific methodological problems in our study related to 
study design, patient selection, case definition and statistics.  
8.4.2 Study design and patient selection 
 
For a study to be methodologically sound and feasible in relation to the study purpose 
it is required to use the right design. There are some standard terms for study design 
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which are related to different epistemological levels. One can distinguish between 
experimental (such as double-blind randomised controlled trial) and observational 
studies, which can be retrospective record reviews or prospective studies. 
Furthermore, studies can be cross-sectional or longitudinal.  
In this thesis, a variety of study designs were used to explore different aspects of PD 
and depression. First, a prevalence study (community-based) was conducted to 
estimate the prevalence of PD in the population of Rogaland/Norway. Subsequently, 
the cohort was examined longitudinally (longitudinal cohort study) over time. 
However, the assessments at a single point in 1993, 1997, and 2001 and so on, are 
cross-sectional studies. So, even if some of the studies presented in this thesis 
represent cross-sectional data, it is important to stress that it contributes to the quality 
of data, that these data are based on a unselected cohort followed prospectively for 
many years. This increases the diagnostic accuracy of PD and dementia.  
Another matter of discussion is, if the chosen operational procedure employed in a 
prevalence study really results in a complete detection of all subjects of interest. 
Moreover, it is important to know where the study subjects come from and if they are 
an appropriate group to study to address the research question of interest. It is of 
interest to know how the study subjects are selected. Are they a sub-sample from a 
larger population based study or are they taken from a selected randomized controlled 
trial? A typical selection bias is to base studies on groups from in- or outpatient 
samples or include patients based on retrospective hospital charts. Such samples are 
usually biased, since for example nursing home patients or patients treated by the 
general practitioner are underrepresented. Accordinly, such study samples may be 
younger and have more severe or more atypical features than the general population 
of patients. 
In our study, to ensure a case-ascertainment as complete as possible, all available 
information regarding specific diseases were considered. This included hospital files, 
but also information from the Rogaland Parkinson’s Society, all general practitioners, 
health workers, district nurses and nursing homes from the recruitment. However, 
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early cases not diagnosed yet were not included. In general, door-to-door surveys 
may be the best method with the highest level of response and they also ensure to 
target persons not consulting their general practitioner. However, taken our resources 
into consideration, we think, our approach of patient selection was the best possible 
and that nearly all individuals in our study area suffering from PD in January 1993 
were included.  
During the first years of follow up, the time interval between the study visits was four 
years. Such a long test-interval leads to relatively high attrition rate in this rather old 
and frail population, primarily due to death. Attrition due to other causes was very 
low. Thus, we think that even in our follow-up sample selective attrition is not a 
confounder, and that the group is representative for the PD population in the region. 
8.4.3 Diagnosis of PD and psychometric methods 
 
The application of appropriate diagnostic and rating instruments is another essential 
condition in epidemiological research. In our study, we aimed to apply standardized 
and well established instruments with adequate psychometric properties.  
The diagnosis of PD is still based on clinical examination. With the exception of 
dopamine transporter scan, which was not available at the start of the main study, 
there are no biomarkers yet which can ascertain the diagnosis during lifetime. 
Clinical examination includes a careful disease history and the application of 
diagnostic criteria. One aim in epidemiological research is to detect all patients with 
the disease which has to be studied (sensitivity). For the experienced clinician, it is 
usually not difficult to identify patients with parkinsonism, although mild and 
atypical cases can be difficult to identify. It may be more difficult and therefore a 
larger methodological issue in PD research, to achieve high specificity, i.e. to exclude 
all those cases with conditions mimicking idiopathic PD, like parkinsonism in  DLB 
or frontotemporal dementia , vascular parkinsonism, parkinsonism as side effect after 
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administration of specific drugs, essential tremor and parkinsonism as clinical 
syndrome in the so-called Parkinson plus syndromes. 
The gold standard in the diagnosis of PD is the application of UK-Parkinson’s 
Disease Society Brain Bank (UK-PDS-BB) criteria 170. These criteria were used in 
study 2 and 3. In our sample 1, PD was diagnosed regarding to diagnostic criteria 
published by Larsen et al. 2. When published in 1993, these criteria were one of the 
first attempts to systematize the diagnosis of PD, and their accuracy was later 
supported neuropathologically in 22 cases that came to autopsy 169, and subsequently 
by a further 7 cases (Robert Perry, personal communication). Moreover, there are no 
substantial differences between UK-PDS-BB criteria and the criteria used in our 
study. 
Another important term in epidemiologic research is validity. To study the validity of 
a rating instrument means to investigate the extent to which the instrument measures 
what we want it to measure. For example does a questionnaire designed to measure 
depression on an ordinal scale actually measure depression as defined by diagnostic 
criteria? And even if validity has been demonstrated previously, has it been 
demonstrated in the setting we want to apply it in? A scale which has been validated 
for use among younger adults may not be valid if used among elderly patients with 
neurological diseases or in other countries. The depression rating scales we used in 
our study are widely used and accepted depression measures. They have subsequently 
been validated for patients with PD against the gold standard, DSM IV criteria for 
“depressive disorder”. Cut-offs for the use of both MADRS (14/15) and BDI (13/14) 
to discriminate between depressed and non-depressed subjects have been 
recommended 176 177. At lower cut-offs, the scales have higher sensitivity and are 
useful screening instruments, at the cost of a low specificity. Vice versa, at higher 
cut-offs the specificity becomes higher, but the sensitivity lower. These features 
suggest that they are good diagnostic instruments.  
While the MADRS represents a clinician-based rating scale, the BDI is a self-report 
method. The choice between clinician-based or self-rating instruments is complex. 
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The latter are easier to administrate and do not require skilled interviewers. But their 
use as diagnostic instruments is restricted by confounders like personality traits. On 
the other hand, for methods of measurement in which the role of an observer is 
crucial, inter-rater reliability (IRR) should be considered. This is relevant if several 
raters administer an instrument, a common situation in multi-centre clinical trials or 
longitudinal studies. Two observers may rate the same phenomenon different, if not 
trained sufficiently. Another situation reducing IRR is when the subject answers 
differently dependent on the social style or personality of the interviewer or the 
presentation of particular questions (interviewer bias). The use of fixed wording 
questions is one method reducing interviewer bias. 
Generally, it is important to improve agreement between observers by training and 
using the same observer when making 'before' and 'after' measurements on the same 
subject. In our department, we are training the psychometric measures we use 
regularly, which enhances IRR. However, no systematic attempts to establish IRR 
coefficients were made in the current studies. 
In study 3, we examined depressive symptoms in patients drawn from a randomized 
controlled trial, who did not suffer from “major depression”. Our study purpose was 
planned post-hoc, i.e. after the original study was conducted. The depression item 
from the NPI 178, was available to assess depression. The psychometric properties of 
the NPI depression item have not yet been established in PD. One strength of this 
item is its focus on the psychological and behavioural sign and symptoms of sadness 
and guilt rather than somatic items or anxiety. The instrument is highly structured 
with scripted questions and anchored responses. However, one should not diagnose 
specific psychiatric disorders based upon the NPI, although we believe that it can be 
used to detect clinical relevant depressive symptoms. In fact, the introducing question 
in the NPI depression domain: “does the patient seem depressed or does he say that 
he is depressed” is commensurable with the question which previously has been 
shown to perform remarkably well in depression case-finding studies 184. In other 
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words, it is likely that a person, who answers “yes” on the question “are you 
depressed?” in fact, is depressed. 
In study 4 on the relationship between pain and depression, the items related to pain 
were selected from the NHP. A genuine pain measure was not used. Originally, the 
NHP was constructed to measure “perceived health”. However,  in studies to estimate 
its concurrent validity, the NHP pain section correlated with 0.78 with the McGill 
Pain Questionnaire 175, supporting its validity as a measure of pain.  
Cognitive functioning was assessed with MMSE in our studies. This well studied 
instrument is used all over the world and is brief enough for routine clinical use. In 
general, validity results appear to be good 185. Some limitations have to been taken 
into consideration. The MMSE has floor and ceiling effects. Low educational level 
predicts lower scores. It may also miss impairments resulting from right hemisphere 
lesions 186. However, the biggest concern in our study is related to the limited 
discriminant validity of the MMSE when used to assess cognitive impairment of the 
subcortical type, which is typical in PD. Especially in the early stages of dementia, 
these patients more often exhibit executive and visuo-spatial impairment, domains 
that are rather underrepresented in the MMSE, which may lead to false negative 
results. In studies examining this issue, patients with PD performed as well as normal 
control subjects on the MMSE. Therefore it is recommended to add more specific 
instruments designed for the assessment of frontal or subcortical dysfunction such as 
Mattis Dementia Rating Scale 187 . More recently, more specific cognitive batteries 
have been developed, including the Montreal cognitive assessment (MoCA) 188 and 
Parkinson’s disease – cognitive rating scale (PD-CRS) 189, which should be employed 
in future studies.  
8.4.4 Findings in context 
Study 1 is the first extensive review of prevalence studies of depression in PD taking 
the different settings and diagnostic approaches of the various studies into account. 
Two earlier reviews on the prevalence of depression in PD have been published, but 
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those did not perform a quality assessment before including studies. Studies which 
did not sufficiently describe patient selection or diagnostic criteria used for 
depression and PD were excluded.  The average prevalence of major depressive 
disorder in PD is 17%, the prevalence of dysthymia is 13%, while minor depression 
occurs more frequently in 22% of PD patients. These prevalence numbers are 
somewhat lower than previously reported 24, but our review nevertheless confirms 
that depression is a common complication in patients with PD. As expected, in 
studies from the general population the numbers are lower, while they are higher in 
hospital outpatient and inpatient settings. A review is influenced by the limitations of 
the included studies themselves. One limitation is the fact that the relationship 
between psychopharmacological medication and the prevalence rate of depressive 
disorder was not examined in most reviewed studies. The fact that PD patients may 
be successfully treated with an antidepressant may therefore have lead to under-
reporting the frequency in this review. Another issue is the limited declaration of the 
time interval the reported prevalence numbers refer to. Many studies failed to 
distinguish precisely between present MD and MD in remission, which made it 
difficult to determinewhether the reported numbers were prevalence ore lifetime 
prevalence rates.  
In our study on the depressive symptom profile, the clinical phenotype of depression 
in PD differed from that in depressed patients without PD, with less experienced 
sadness and guilt, and more anxiety and concentration difficulties. This is consistent 
with previous studies of depressed PD patients 49 52 190, studies which did not include 
non-PD patients. This suggests that there are different etiological mechanisms 
underlying depression in people with and without PD, or that the symptoms of PD 
influence the depression phenomenology. Energy loss was more marked in non-PD 
than PD patients. We know that apathy is not identical to depression 191, but the 
clinical distinction between “loss of energy” as a depressive symptom and apathy is 
difficult. Apathy is particularly common in PD 26, and therefore, our finding was 
unexpected. Possibly, PD patients underreport their “loss of energy” (apathy) because 
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they may not suffer from it to the same extent, they may attribute this to PD, or may 
have become used to this change after many years of PD. 
The proportion with sub threshold depression in PDD (study 3) was 21%, which is 
similar to the 18% with minor depression in overall PD found in Study 1. This 
finding underlines previous research showing that depression is an important clinical 
issue even if MD criteria are not fulfilled, particularly in elderly and somatically ill 
people. Furthermore, it suggests that minor depression is not more common in PDD 
than in PD, although this has not yet been studied specifically. On the other hand, an 
association between depression and cognitive impairment in PD has been frequently 
reported 25 66 115. One possible explanation for this possible inconsistency is that major 
depression, but not minor depression, is associated with dementia in PD. Findings 
consistent with this hypothesis have been reported 55. One potential explanation for 
this is that major depression in PD is more closely related to the brain changes 
associated with dementia in PD compared to minor depression. The association 
between depression and left-sided parkinsonism and young age at onset in males is 
consistent with previous studies 192. The lack of such associations in female patients 
suggests potential gender differences in the underlying biology of depression.  
Study 4 is the largest study to date showing an association between pain and 
depression in PD. Previously, only case reports 193 194 and two small studies without a 
control group 86 87 have been reported, showing comparable results. The proportion of 
subjects having a clinical depression score suggestive of major depression was three 
times higher among those with pain compared to those without pain. Since this was a 
cross-sectional study, the direction of causality cannot be determined, and the relative 
importance of psychological and biological contributing factors remains unknown. 
However, our results support the hypothesis that pain may cause or interfere with 
depression also in PD. The most interesting finding in Study 5 was that 5HT1a 
receptor density in temporal cortex was increased in depressed patients with PDD. 
Previous CSF and imaging studies have suggested that serotonergic mechanisms may 
contribute to depression in PD. This is the first autopsy study exploring the 
 60
serotonergic system in PD patients with depressive symptoms. One interpretation of 
the finding is that a secondary up-regulation due to serotonergic deficit has occurred. 
Taken together, based on the findings in studies 4 and 5, we propose that both brain 
changes and psychological factors interact in the aetiology of depression in PD. 
Drugs with anticholinergic activity are frequently used by patients with PD. In Study 
6 we observed for the first time, that the duration and dosage of the use of such drugs 
were associated with a more rapid cognitive decline in PD. Similar findings have 
been reported in clinical studies in elderly people and in patients with dementia 195. 
The finding is also consistent with autopsy studies reporting more severe Alzheimer-
type brain changes in PD patients 119  and DLB patients 196  who had used 
anticholinergic agents compared to patients who had not used such drugs, and vice 
versa, that cholinergic agents are associated with less severe senile plaques 197. 
However, a recent report suggests that cholinergic drugs were associated with more 
severe tangle pathology in DLB 196. Further studies of these important questions are 
needed. 
8.4.5 Implications  
Our systematic review of prevalence studies of depression in PD confirmed the high 
percentage of patients with this common neurodegenerative disorder, who 
additionally suffer from depression. As depression is one main contributor to 
impaired quality of life, our results underline how important it is to identify patients 
with this condition and to treat it.  
We found a somewhat differing depression symptom profile in PD patients compared 
to depressed people without PD. This may have implications for diagnosis. Typical 
depressive symptoms like feelings of guilt may be less common than in patients with 
other depressive syndromes, especially endogenous depression. We also speculate 
that the depressive symptom profile in PD patients reflects a neurotransmitter 
deficiency differing from that in common depression. Thus, depression in PD might 
be more related to noradrenergic deficiency than depression in non-PD subjects. This 
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may have therapeutic implications. At present there is limited evidence available to 
guide the choice of antidepressive therapy in PD. The recently published study on 
nortriptyline against paroxetine and placebo support the hypothesis that drugs with 
affinity to different receptors are superior to drugs with just serotonergic mechanism 
146. 
The strong association between pain and depression in PD has several implications. 
We propose that pain assessment should be a regular component of care in PD, 
particularly in those with depression. Moreover, further research should examine, if 
active pain management can improve depression and thus quality of life in PD 
patients. This may include both pharmacological and physical treatment. 
We discovered 60% higher 5-HT 1A receptor density in the temporal cortex (BA36) 
in DLB/PDD subjects in the presence of depressive behaviour relative to those 
patients who had never experienced depression. This finding should be replicated and 
examined further. The interactions between different neurotransmitters involved in 
depression in PD and their interdependent up- and down-regulation in different brain 
areas are not completely understood yet but may have important implications for 
developing effective treatments for depression. We speculate that drugs with 5HT1a 
activity may be particularly effective in PDD patients with depression, and clinical 
trials are warranted. 
Drugs with anticholinergic properties are frequently prescribed to patients with PD 
and were associated with more rapid cognitive impairment. These findings have 
implications for the management of PD patients, since avoiding such drugs may 
avoid increasing progression of cognitive decline, and highlight the need for 
continued physician education to ensure avoidance of inadvertent prescription of such 
drugs. Clinicopathological studies should examine the association between 
morphological changes, cognitive impairment, and anticholinergic drug 
administration in PD. 
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